Neurol. pro Praxi, 2005; 3: 140-148

1H in vivo MR spektroskopie v klinické neurologii

Ing. Zenon Starčuk, DrSc.1, doc. MUDr. Petr Krupa, CSc.2, Ing. Zenon Starčuk jr., CSc.1, Ing. Jaroslav Horký1
1 Ústav přístrojové techniky AV ČR, Brno
2 Klinika zobrazovacích metod LF MU, FN u sv. Anny v Brně

V předloženém příspěvku jsou stručně popsány některé ze základních charakteristik in vivo protonové (1H) MR spektroskopie zejména ve vztahu k jejímu využití v klinické neurologické praxi. Je posouzen vliv volby intenzity magnetického pole a akviziční techniky na kvalitu získávaných protonových MR spekter. V závěru příspěvku jsou stručně uvedeny některé z nejdůležitějších klinických neurologických aplikací 1H in vivo MRS.

Keywords: Klíčová slova: magnetická rezonance, H-1 MR spektroskopie, jednovoxelové techniky MRS, spektroskopické zobrazování, klinické aplikace H-1 MRS.

Published: February 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Starčuk Z, Krupa P, Starčuk Z, Horký J. 1H in vivo MR spektroskopie v klinické neurologii. Neurol. praxi. 2005;6(3):140-148.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Burtscher IM, Holtas S. Proton MR spectroscopy in clinical routine. J Magn Reson Imaging 2001; 13: 560-567. Go to original source... Go to PubMed...
    2. Chu WJ, Kuzniecky RI, Hugg JW, et al. Statistically driven identification of focal metabolic abnormalities in temporal lobe epilepsy with corrections for tissue heterogeneity using 1H spectroscopic imaging. Magn Reson Med 2000; 47: 195-200. Go to original source...
    3. Danielsen ER, Ross B. Magnetic resonance spectroscopy of neurological diseases. New York: Marcel Dekker, 1999. Go to original source...
    4. Devos A, Lukas L, Suykens JAK, Vanhamme L, et al. Classification of brain tumors using short echo time 1H MR spectra. J Magn Reson 2004; 170: 164-175. Go to original source... Go to PubMed...
    5. Dowling C, Bollen AW, Noworolski SM, et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathological analysis of resection specimens. American Journal of Neurology 2001; 22: 604-612.
    6. Hagberg G, Burlina AP, Mader I, Roser W, et al. In vivo proton MR spectroscopy of human gliomas; definition of metabolic coordinates for multi-dimensional classification. Magn Reson Med 1995; 34: 242-252. Go to original source... Go to PubMed...
    7. Hammen T, Stefan H, et al. Clinical applications of 1H-MR spectroscopy in the evaluation of epilepsies - What do pathological spectra stand for with regard to current results and what answers do they give to common clinical questions concerning the treatment of epilepsies? Acta Neurol Scand 2003; 108: 223-238. Go to original source... Go to PubMed...
    8. Howe FA, Barton SJ, Cudlip SA, Stubbs M, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003; 49: 223-232. Go to original source... Go to PubMed...
    9. Jackson JD, Connely A. New NMR measurements in epilepsy. T2 relaxometry and magnetic resonance spectroscopy. Adv Neurol 1999; 79: 931-937.
    10. Kreis R, Quantitative localized 1H-MR spectroscopy for clinical use. Prog. NMR Spectroscopy 1997; 31: 155-195. Go to original source...
    11. Kugel H, Heindel W et al. Human brain tumors: spectral patterns detected with localized H-1 MR spectroscopy. Radiology 1992; 186: 701-709. Go to original source... Go to PubMed...
    12. Kuzniecky R, Hugg JW, Abou-Khalil B, et al. Predictive value of 1H MRSI for outcome in temporal lobectomy. Ann Neurol 1999; 53: 694-698. Go to original source... Go to PubMed...
    13. Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt AW. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002; 222: 715-721. Go to original source... Go to PubMed...
    14. Mukherji SK. Clinical applications of MR spectroscopy. New York: Wiley-Liss 1998. 317 s.
    15. Schlemmer HP, Bachert P, Henze M, Buslei R et al. Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy. Neuroradiology 2002; 44: 216-222. Go to original source... Go to PubMed...
    16. Tate AR, Majos C, Moreno A, et al. Automated classification of short echo time in vivo 1H MR brain tumor spectra: a multicenter study. Magn Reson Med 2003; 49: 29-36. Go to original source... Go to PubMed...
    17. Tkáč I, Starčuk Z, Choi IY, Gruetter R. In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. J Magn Reson 1999; 41: 649-656. Go to original source...
    18. Tofts PS, Spectroscopy: 1H metabolite concentrations, in quantitative MRI of the brain. John Wiley & Sons 2003; 299-339. Go to original source...
    19. Tong Z, Yamaki T, Harada K, Houkin K. In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard. Magn Reson Imaging 2004; 22: 1017-1024. Go to original source... Go to PubMed...
    20. Vermathen P, Laxer KD, Matson GB, Weiner MW. Hippocampal structures: anteroposterior N-acetylaspartate differences in patients with epilepsy and control subjects as shown with with proton MR spectroscopic imaging. Radiology 2000; 214: 403-410. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.